Research Summary

Low Adherence to Timely Opioid Administration for Acute Sickle Cell Disease Pain

Edited by:
Ashton L. Stahl

Key Highlights

  • Only 32.5% of emergency department visits met guideline recommendations for first-dose opioid timing.
  • Second-dose adherence was markedly lower at 9.0%, with oral opioids outperforming parenteral routes.
  • Children and male patients were more likely to receive guideline-adherent care.
  • Findings reflect data from 394,725 visits across 228 US sites.

Timely analgesia is essential for managing acute sickle cell disease (SCD) pain, yet national reports have long signaled suboptimal adherence to established care standards. A new analysis published at the 67th American Society of Hematology (ASH) Annual Meeting in Orlando, FL, evaluated guideline adherence for opioid administration across more than 200 US health systems, offering one of the most comprehensive assessments to date. The study examined whether emergency departments (ED) met recommendations from ASH and the National Heart, Lung, and Blood Institute, specifically, administering an initial opioid dose within 60 minutes of arrival and subsequent doses within 30 to 60 minutes.

Researchers analyzed de-identified electronic health record data from the Epic Cosmos platform, including ED visits from January 1, 2019, to December 31, 2024. Eligible encounters included patients with a primary ICD-10 diagnosis indicating SCD pain crisis who received at least 1 opioid. Visits associated with complications were excluded. The investigators calculated guideline adherence rates for first and second opioid doses and stratified results by age, sex, route of administration, payer status, historical ED utilization, and acuity level. Chi-square tests were used to evaluate associations between these factors and adherence.

Study Findings

Across 394,725 ED visits involving 40,977 unique patients, the median patient age was 31 years, and 55.2% of visits involved female patients. Public insurance accounted for three-quarters of encounters.

Overall, only 32.5% of visits met the guideline for administering the first opioid dose within 60 minutes of arrival (95% CI, 32.4%–32.6%). Among the 302,738 visits requiring multiple doses, just 9.0% met the recommended timing for the second dose (95% CI, 8.9%–9.1%).

Route of administration did not affect first-dose adherence. However, oral opioids demonstrated higher second-dose adherence (24.3%; 95% CI, 23.7%–24.8%) compared with parenteral administration (7.7% [95% CI, 7.6%–7.8%]; [P < .001]).

Younger patients (≤ 19 years) received more timely care: 52.0% achieved on-time first doses compared with 29.6% of adults (P < .001), a pattern that persisted for second-dose timing. Male patients were also more likely to receive guideline-adherent care than female patients for both first (36.9% vs 28.9%) and second doses (10.6% vs 7.7%). Payment type, past ED utilization, and acuity level were not associated with adherence.

Clinical Implications

According to the study authors, these findings highlight persistent gaps in meeting national standards for timely pain management in SCD. The authors note that adherence remains low across demographic groups and care settings, underscoring the need for targeted quality improvement efforts. The observed differences by age and sex may provide actionable insights for systems aiming to reduce disparities in emergency pain treatment.

Expert Commentary

“Guideline-adherence for the timely delivery of opioid pain medication for acute SCD pain is inadequate, with fewer than one-third of patients receiving a first dose on time and fewer than one in ten receiving a timely second dose,” the researchers concluded.

Reference

Gwarzo I, Dega HC, Brousseau D. Multicenter evaluation of guideline adherence for the timeliness of pain medication for acute sickle cell disease pain. Abstract 121. Presented at: 67th American Society of Hematology Annual Meeting; Orlando, FL; 2024. https://submit.hematology.org/program/presentation/676258.